Life Science News

Latest updates from the biotech and pharma world

BioPharma Dive 2026-02-20

Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi

Endpoints News 2026-02-20

Novartis to divest India unit to private equity-led consortium for $159M

FierceBiotech 2026-02-20

Daiichi picks former Novartis CMO John Tsai to head up R&D

FierceBiotech 2026-02-19

Novartis winds down ph. 1 solid tumor program after lacking efficacy

FierceBiotech 2026-02-18

Novartis finds natural partner in macrocycle biotech, inking $1.7B-plus cardio deal

Endpoints News 2026-02-18

Updated: Novartis signs macrocyclic deal with Unnatural Products

Endpoints News 2026-02-18

Novartis signs macrocyclic deal with Unnatural Products for $100M upfront

Endpoints News 2026-02-18

Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results

FierceBiotech 2026-02-04

Novartis shakes up early pipeline with 6 culls and 2 new cancer candidates

Endpoints News 2026-02-04

Novartis says generics to erode $4B from 2026 sales

BioWorld 2026-01-21

Novartis discovers new CDK inhibitors

Endpoints News 2026-01-13

Novartis licenses radiopharma asset from Chinese biotech for $50M upfront

Endpoints News 2026-01-12

Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s

Endpoints News 2026-01-09

Novartis to build fourth US radiotherapy factory in Florida

Endpoints News 2025-12-18

Alnylam, INCOG and Novartis expand in US; Ember gets $16.5M Series A

Roche Media 2025-12-18

Roche and Novartis close to price agreement with Trump - medwatch.com

FierceBiotech 2025-12-18

Voyager jettisons 30 employees, Novartis hands back rights to 2 programs

BioPharma Dive 2025-12-09

Novartis notches another win for drug acquired in MorphoSys deal

Endpoints News 2025-12-09

Novartis to partner with AI-focused Relation on atopic diseases

FierceBiotech 2025-12-09

ASH: Novartis details ianalumab's phase 3 win in rare blood disease

-2 / 2